| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
688.57(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.86 - $18.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 17.6 |
| Insider 3/6 Months : 18.2 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the U.S. Food and Drug Administration for the treatment, in combination with Granulocyte-Macrophage Colony-Stimulating Factor of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
558,056 |
761,536 |
762,731 |
| Total Buy Value |
$0 |
$3,530,830 |
$5,493,638 |
$5,499,522 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
14 |
16 |
17 |
| Total Shares Sold |
7,293 |
307,293 |
307,293 |
307,293 |
| Total Sell Value |
$120,236 |
$1,916,619 |
$1,916,619 |
$1,916,619 |
| Total People Sold |
3 |
3 |
3 |
3 |
| Total Sell Transactions |
3 |
8 |
8 |
8 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tagliaferri Mary |
Director |
– • – |
2024-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
4,660 |
4,660 |
|
- |
|
| Smith Susan Laura |
SVP & CHIEF COMMERCIAL OFFICER |
• – – |
2024-03-05 |
4 |
S |
$16.55 |
$27,837 |
D/D |
(1,682) |
33,918 |
|
-3% |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-03-05 |
4 |
S |
$16.44 |
$64,116 |
D/D |
(3,900) |
158,700 |
|
-3% |
|
| Rajah Vignesh |
SVP & CHIEF MEDICAL OFFICER |
• – – |
2024-03-05 |
4 |
S |
$16.53 |
$28,283 |
D/D |
(1,711) |
33,889 |
|
-3% |
|
| Rossi Michael J |
PRESIDENT & CEO |
• • – |
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
35,700 |
35,700 |
|
- |
|
| Rajah Vignesh |
SVP & CHIEF MEDICAL OFFICER |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
| Kruse Bo |
EVP, CFO, SECRY & TREAS. |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
18,100 |
210,877 |
|
- |
|
| Smith Susan Laura |
SVP & CHIEF COMMERCIAL OFFICER |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
| Wilms Joris |
SVP & CHIEF OPERATING OFFICER |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
| Lisby Steen |
SVP & CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
| Lund-Hansen Torben |
SVP & CHIEF TECHNICAL OFFICER |
• – – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
17,800 |
35,600 |
|
- |
|
| Gad Thomas |
CHIEF BUSINESS OFFICER |
• • – |
2024-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
22,100 |
162,600 |
|
- |
|
| Gad Thomas |
Chief Business Officer |
• • – |
2023-12-21 |
4 |
OE |
$2.00 |
$100,000 |
D/D |
50,000 |
140,500 |
|
- |
|
| Gad Thomas |
Chief Business Officer |
• • – |
2023-12-15 |
4 |
S |
$6.61 |
$330,500 |
I/I |
(50,000) |
265,032 |
|
-134% |
|
| Gad Thomas |
Chief Business Officer |
• • – |
2023-12-14 |
4 |
S |
$6.83 |
$341,500 |
I/I |
(50,000) |
315,032 |
|
-113% |
|
| Gad Thomas |
Chief Business Officer |
• • – |
2023-12-13 |
4 |
S |
$6.58 |
$329,000 |
I/I |
(50,000) |
365,032 |
|
-117% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2023-12-11 |
4 |
B |
$6.85 |
$44,232 |
I/I |
6,455 |
4,559,233 |
2.1 |
130% |
|
| Wg Biotech Aps |
Director |
– • – |
2023-12-11 |
4 |
B |
$6.85 |
$44,232 |
D/D |
6,455 |
4,559,233 |
2.39 |
130% |
|
| Wg Biotech Aps |
Director |
– • – |
2023-12-11 |
4 |
B |
$7.01 |
$720,843 |
D/D |
102,863 |
4,552,778 |
2.39 |
130% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2023-12-11 |
4 |
B |
$7.01 |
$720,843 |
I/I |
102,863 |
4,552,778 |
2.1 |
130% |
|
| Wg Biotech Aps |
Director |
– • – |
2023-12-08 |
4 |
B |
$6.99 |
$129,379 |
D/D |
18,503 |
4,449,915 |
2.39 |
114% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2023-12-08 |
4 |
B |
$6.99 |
$129,379 |
I/I |
18,503 |
4,449,915 |
2.1 |
114% |
|
| Wg Biotech Aps |
Director |
– • – |
2023-12-07 |
4 |
B |
$6.50 |
$40,190 |
D/D |
6,183 |
4,431,412 |
2.39 |
121% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2023-12-07 |
4 |
B |
$6.50 |
$40,190 |
I/I |
6,183 |
4,431,412 |
2.1 |
121% |
|
| Wedell-Wedellsborg Johan |
Director |
– • – |
2023-11-29 |
4 |
B |
$5.97 |
$309,477 |
I/I |
51,837 |
4,425,229 |
2.1 |
131% |
|
249 Records found
|
|
Page 1 of 10 |
|
|
0.03 (0.17%) 
